Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Liothyronine for HFpEF and Low T3 Syndrome
NCT04111536Phase 2Completed
- Sponsor
- University of Pennsylvania
- Start
- Mar 2020
- Primary completion
- Oct 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of liothyronine in heart failure with preserved ejection fraction (HFpEF) and Low triiodothyronine syndrome (NTIS) (2 arms), sponsored by University of Pennsylvania. Primary endpoints: Number of Participants With Atrial Fibrillation or Ventricular Tachycardia >=4 Beats at 14 days and Triiodothyronine Level at 8 weeks. Started Mar 2020; status: completed.
02
Drugs
liothyronine
03
Conditions
heart failure with preserved ejection fraction (HFpEF)Low triiodothyronine syndrome (NTIS)
Beyond the preview
Go deeper on NCT04111536.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04111536.